Search results for "bronchodilator agents"

showing 10 items of 104 documents

Getting new bronchodilator compounds from molecular topology.

2003

Abstract Molecular topology has been used to select new lead bronchodilator compounds. The main advantage of this method, as compared to others frequently used, is that it does not require a previous explicit knowledge of the mechanism of action (MOA) of the compounds analyzed. A large database (12,000 chemicals) has been examined in this study to find less than 5% compounds with bronchodilator activity. After removing those compounds already described as bronchodilators, we present here the results for 20 among these compounds, some of them showing other pharmacological activities. Some of the compounds selected in this study showed higher relaxation and higher potency than theophylline, w…

IndolesChemistrymedicine.drug_classMolecular ConformationPharmaceutical SciencePharmacologyModels TheoreticalReference drugBronchodilator AgentsStructure-Activity RelationshipPharmaceutical technologyEllagic AcidTheophyllineBronchodilatormedicinePotencyTheophyllineMolecular topologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Inhalation solutions — Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers — Update 2013

2014

AbstractMany patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in vitro studies and a thorough literature search.Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients contained in some of the tested drug products could be identified as a reason for i…

Lung DiseasesPulmonary and Respiratory MedicineDrugmedicine.medical_specialtymedia_common.quotation_subjectReviewCompatibilityAdministration InhalationmedicineMixtureHumansPediatrics Perinatology and Child HealthClinical efficacyIntensive care medicineAerosolmedia_commonInhalationbusiness.industryNebulizers and VaporizersDornase alfaAnti-Bacterial AgentsBronchodilator AgentsChemical compatibilityDrug CombinationsNebulizerNebulizer solution/suspensionAnesthesiaChronic DiseasePediatrics Perinatology and Child Healthbusinessmedicine.drugJournal of Cystic Fibrosis
researchProduct

Inhaled Surfactant in the treatment of accidental Talc Powder inhalation: a new case report

2011

Abstract The use of talcum powder is incorrectly part of the traditional care of infants. Its acute aspiration is a very dangerous condition in childhood. Although the use of baby powder has been discouraged from many authors and the reports of its accidental inhalation have been ever more rare, sometimes new cases with several fatalities have been reported. We report on a patient in which accidental inhalation of baby powder induced severe respiratory difficulties. We also point out the benefits of surfactant administration. Surfactant contributed to the rapid improvement of the medical and radiological condition, preventing severe early and late complications and avoiding invasive approac…

Lung Diseasesmedicine.medical_specialtymedicine.medical_treatmentTreatment outcomeCase Reportmacromolecular substancesTalcSettore MED/38 - Pediatria Generale E SpecialisticaPulmonary surfactantAdministration InhalationSurfactantmedicineHumansTalcum powderRespiratory physiotherapyIntensive care medicinePhospholipidsBiological ProductsInhalationRespiratory distressbusiness.industrylcsh:RJ1-570InfantRespiratory Physiotherapylcsh:PediatricsPulmonary SurfactantsBronchopulmonary LavageAccidental InhalationAnti-Bacterial AgentsBronchodilator AgentsRadiographyTreatment OutcomeCoughBaby powderTalcRespiratory DistressAccidentalDrug Therapy CombinationFemaleInhaled surfactant talc powder inhalationPowdersbusinessmedicine.drugItalian Journal of Pediatrics
researchProduct

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Background: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect. Methods: Human sputum and blood neutrophils were isolated from healthy individuals ( n = 37), patients with stable COPD ( n = 52) and th…

Male0301 basic medicineNeutrophilsVesicular Acetylcholine Transport ProteinsAnti-Inflammatory AgentsDrug ResistanceNon-neuronal cholinergic systemPulmonary Disease Chronic Obstructive0302 clinical medicineMuscarinic acetylcholine receptorCOPDDrug SynergismAclidinium bromideMuscarinic acetylcholine receptor M2Middle AgedReceptors MuscarinicBronchodilator AgentsCorticosteroidDrug Therapy CombinationFemaleInflammation Mediatorsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyCombination therapymedicine.drug_classCorticosteroid resistanceMuscarinic AntagonistsFluticasone propionateCholine O-Acetyltransferase03 medical and health sciencesAclidinium bromideInternal medicinemedicineHumansCOPDAgedDose-Response Relationship Drugbusiness.industryResearchSputumMuscarinic antagonistmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemCase-Control StudiesFluticasonebusinessTropanesRespiratory Research
researchProduct

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct

Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controll…

2006

To evaluate the efficacy and tolerability of a novel hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) formulation of budesonide (Pulmicort) versus the conventional chlorofluorocarbon (CFC) pMDI formulation in paediatric patients with asthma.This was a Phase III, multicentre, 12-week, double-blind, randomised, parallel-group study involving children (6-12 years of age) with mild to moderate asthma. Patients received either budesonide HFA pMDI or budesonide CFC pMDI 200 mug twice daily, with or without a spacer (NebuChamber/Nebunette). Primary efficacy endpoint: mean percentage change in forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Secondary efficacy …

MaleBudesonideVital capacityHydrocarbons FluorinatedPeak Expiratory Flow Ratelaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawmedicineHumansMetered Dose InhalersBudesonideChildAsthmaChlorofluorocarbonbusiness.industryInhalerGeneral Medicinemedicine.diseaseMetered-dose inhalerAsthmaBronchodilator AgentsTreatment OutcomeAerosol PropellantschemistryTolerabilityAnesthesiaFemaleChlorofluorocarbonsbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

EFFECTS OF CROMAKALIM (BRL-34915) IN TRACHEA ISOLATED FROM ACTIVELY SENSITIZED GUINEA-PIGS

1993

Abstract The effects of cromakalim were examined in tracheal strips isolated from normal (unsensitized) guinea-pigs and from animals actively sensitized to bovine serum albumin. Sensitized tracheae exhibited hyper-responsiveness to KCl, acetylcholine and histamine. In normal and sensitized tracheae, cromakalim (0·01–10 μm) produced a concentration-related suppression of spontaneous tone. The ability of cromakalim to relax tracheal strips was reduced when tone was raised by KCl (25 Mm), acetylcholine (0·1 Mm) or histamine (0·1 Mm) and lost against KCl (120 Mm)-induced spasm. Procaine (5 Mm) abolished the relaxant effect of cromakalim whilst tetraethylammonium (8 Mm) was without effect. These…

MaleCromakalimPotassium ChannelsGuinea PigsPharmaceutical SciencePharmacologyGuinea pigchemistry.chemical_compoundProcainemedicineAnimalsBenzopyransPyrrolesBovine serum albuminPharmacologyTetraethylammoniumbiologyChemistryMuscle SmoothSerum Albumin BovineAcetylcholineBronchodilator AgentsTracheaKineticsmedicine.anatomical_structureAnesthesiaMuscle Tonusbiology.proteinPotassiumFemaleImmunizationCromakalimAcetylcholineHistaminemedicine.drugRespiratory tractHistamine
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Pharmacological activity of PF-904 in guinea pig in vivo, and on human bronchus and neutrophils in vitro.

1997

The effects of PF-904 (4-amino-1-ethyl-6-methylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide), a pyrazinothiadiazine derivative, were examined in guinea-pig airways in vivo, in human isolated bronchus and human polymorphonuclear leukocytes. PF-904 (12.5-200 mg/kg, intraduodenal) reduced bronchoconstriction in response to histamine, arachidonic acid, platelet-activating factor (PAF) and methacholine. PF-904 (50-200 mg/kg) prevented PAF-induced airways hyperreactivity and inhibited antigen-induced bronchoconstriction, airway microvascular leakage and eosinophil lung accumulation, but antigen-induced airways hyperresponsiveness was not reduced. PF-904 (1 microM-1 mM) produced complete inhibiti…

MaleNeutrophilsPhosphodiesterase InhibitorsGuinea PigsBronchiPharmacologyIn Vitro TechniquesBronchial Provocation TestsCapillary Permeabilitychemistry.chemical_compoundIn vivoSuperoxidesmedicineAnimalsHumansAnti-Asthmatic AgentsPlatelet Activating FactorRolipramPharmacologyBronchusThiadiazinesAnti-Inflammatory Agents Non-SteroidalPhosphodiesteraseBiological activityrespiratory systemBronchodilator AgentsN-Formylmethionine Leucyl-Phenylalaninemedicine.anatomical_structurechemistryBiochemistryPyrazinesBronchoconstrictionMethacholinemedicine.symptomBronchial HyperreactivityHistaminemedicine.drugEuropean journal of pharmacology
researchProduct